|
1
|
PDQ Adult Treatment Editorial Board, .
Non-small cell lung cancer treatment (PDQ®): Patient
version. NCI. May 12–2002–2015.
|
|
2
|
Soria JC, Mok TS, Cappuzzo F and Jänne PA:
EGFR-mutated oncogene addicted non-small cell lung cancer: Current
trends and future prospects. Cancer Treat Rev. 38:416–430. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nguyen KS and Neal JW: First-line
treatment of EGFR-mutant non-small cell lung cancer: The role of
erlotinib and other tyrosine kinase inhibitors. Biologics.
6:337–345. 2012.PubMed/NCBI
|
|
4
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to Gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu PF, Zhu YP, Yang CH, Wang YF and Wang
GH: The mechanism and countermeasures on the secondary resistance
of epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI). Anti Tumor Pharmacy. 5:42015.
|
|
6
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Robert G, Gaggioli C, Bailet O, Chavey C,
Abbe P, Aberdam E, Sabatié E, Cano A, de Herreros Garcia A,
Ballotti R and Tartare-Deckert S: SPARC represses E-cadherin and
induces mesenchymal transition during melanoma development. Cancer
Res. 66:7516–7523. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: Mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
11
|
Neel DS and Bivona TG: Secrets of drug
resistance in NSCLC exposed by new molecular definition of EMT.
Clin Cancer Res. 19:3–5. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Uramoto H, Iwata T, Onitsuka T, Shimokawa
H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in
EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res.
30:2513–2517. 2010.PubMed/NCBI
|
|
13
|
Yao Z, Fenoglio S, Gao DC, Camiolo M,
Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V,
et al: TGFb IL-6 axis mediates selective and adaptive mechanisms of
resistance to molecular targeted therapy in lung cancer. Proc Natl
Acad Sci USA. 107:15535–15340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tatnell PJ, Powell DJ, Hill J, Smith TS,
Tew DG and Kay J: Napsins: New human aspartic proteinases.
Distinction between two closely related genes. FEBS Lett.
441:43–48. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brasch F, Ochs M, Kahne T, Guttentag S,
Schauer-Vukasinovic V, Derrick M, Johnen G, Kapp N, Muller KM,
Richter J, et al: Involvement of napsin A in the C- and N-terminal
processing of surfactant protein B in type-II pneumocytes of the
human lung. J Biol Chem. 278:49006–49014. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ueno T, Linder S, Na CL, Rice WR,
Johansson J and Weaver TE: Processing of pulmonary surfactant
protein B by napsin and cathepsin H. J Biol Chem. 279:16178–16184.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki A, Shijubo N, Yamada G, Ichimiya S,
Satoh M, Abe S and Sato N: Napsin A is useful to distinguish
primary lung adenocarcinoma from adenocarcinomas of other organs.
Pathol Res Pract. 201:579–586. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chuman Y, Bergman A, Ueno T, Saito S,
Sakaguchi K, Alaiya AA, Franzén B, Bergman T, Arnott D, Auer G, et
al: Napsin A, a member of the aspartic protease family, is
abundantly expressed in normal lung and kidney tissue and is
expressed in lung adenocarcinomas. FEBS Lett. 462:129–134. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schauer-Vukasinovic V, Bur D, Kling D,
Grüninger F and Giller T: Human napsin A: Expression,
immunochemical detection, and tissue localization. FEBS Lett.
462:135–139. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hirano T, Auer G, Maeda M, Hagiwara Y,
Okada S, Ohira T, Okuzawa K, Fujioka K, Franzén B, Hibi N, et al:
Human tissue distribution of TA02, which is homologous with a new
type of aspartic proteinase, napsin A. Jpn J Cancer Res.
91:1015–1021. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirano T, Gong Y, Yoshida K, Kato Y,
Yashima K, Maeda M, Nakagawa A, Fujioka K, Ohira T, Ikeda N, et al:
Usefulness of TA02 (napsin A) to distinguish primary lung
adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer.
41:155–162. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ueno T, Linder S and Elmberger G: Aspartic
proteinase napsin is a useful marker for diagnosis of primary lung
adenocarcinoma. Br J Cancer. 88:1229–1233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ueno T, Elmberger G, Weaver TE, Toi M and
Linder S: The aspartic protease napsin A suppresses tumor growth
independent of its catalytic activity. Lab Invest. 88:256–263.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Slack JL, Bi W, Livak KJ, Beaubier N, Yu
M, Clark M, Kim SH, Gallagher RE and Willman CL: Pre-clinical
validation of a novel, highly sensitive assay to detect
PML-RARalpha mRNA using real-time reverse-transcription polymerase
chain reaction. J Mol Diagn. 3:141–149. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thomson S, Buck E, Petti F, Griffin G,
Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial
to mesenchymal transition is a determinant of sensitivity of non
small cell lung carcinoma cell lines and xenografts to epidermal
growth factor receptor inhibition. Cancer Res. 65:9455–9462. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grunert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng JX, Guan SH, Xu Q, Liu JZ and Song
P: Inhibition of epithelial-mesenchymal transitionin A549 cell by
transfected Napsin A. Chin Med J (Engl). 125:2734–2740.
2012.PubMed/NCBI
|
|
28
|
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada
M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al: N-cadherin
expression and epithelial-mesenehymal transition in pancreatic
carcinoma. Clin Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ruoslahti E: RGD and other recognition
sequences for integrins. Annu Rev Cell Dev Biol. 12:697–715. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Juliano RL: Signal transduction by cell
adhesion receptors and the cytoskeleton: Functions of integrins,
cadherins, selectins, and immunoglobulin-superfamily members. Annu
Rev Pharmacol Toxicol. 42:283–323. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hynes RO: Integrins: Bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Yang J, Dai C, Wu C and Liu Y: Role
for integrin-linked kinase in mediating tubular epithelial to
mesenchymal transition and renal interstitial fibrogenesis. J Clin
Invest. 112:503–516. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bhowmick NA, Zent R, Ghiassi M, McDonnell
M and Moses HL: Integrin beta 1 signaling is necessary for
transforming growth factor-beta activation of p38MAPK and
epithelial plasticity. J Biol Chem. 276:46707–46713. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hauck CR, Sieg DJ, Hsia DA, Loftus JC,
Gaarde WA, Monia BP and Schlaepfer DD: Inhibition of focal adhesion
kinase expression or activity disrupts epidermal growth
factor-stimulated signaling promoting the migration of invasive
human carcinoma cells. Cancer Res. 61:7079–7090. 2001.PubMed/NCBI
|
|
35
|
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK,
Schaefer E, Damsky CH and Schlaepfer DD: FAK integrates
growth-factor and integrin signals to promote cell migration. Nat
Cell Biol. 2:249–256. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sieg DJ, Hauck CR and Schlaepfer DD:
Required role of focal adhesion kinase (FAK) for
integrin-stimulated cell migration. J Cell Sci. 112:2677–2691.
1999.PubMed/NCBI
|
|
37
|
Hauck CR, Hsia DA and Schlaepfer DD: The
focal adhesion kinase a regulator of cell migration and invasion.
IUBMB Life. 53:115–119. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xie B, Zhao J, Kitagawa M, Durbin J, Madri
JA, Guan JL and Fu XY: Focal adhesion kinase activates Stat1 in
integrin-mediated cell migration and adhesion. J Biol Chem.
276:19512–19523. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nam SJ, Kim S, Kim JE, Lim MS,
Elenitoba-Johnson KS, Kim CW and Jeon YK: Aberrant expression
ofnapsinA in a subset of malignant lymphomas. Histol Histopathol.
31:213–221. 2016.PubMed/NCBI
|
